List of Excipients in Branded Drug ALBUTEROL SULFATE INHALATION

Generic Drugs Containing ALBUTEROL SULFATE INHALATION

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals NY LLC	albuterol sulfate	69238-1291	1,1,1,2-TETRACHLORO-2-FLUOROETHANE
Amneal Pharmaceuticals NY LLC	albuterol sulfate	69238-1291	ALCOHOL
The Ritedose Corporation	albuterol sulfate	65302-060	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in ALBUTEROL SULFATE INHALATION?

# Of NDCs	Excipient
1	1,1,1,2-TETRACHLORO-2-FLUOROETHANE
1	ALCOHOL

Albuterol Sulfate Inhalation Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Albuterol sulfate inhalation is a mature, high-volume generic market with limited active-ingredient differentiation. Commercial value is concentrated in excipient selection, inhaler-device performance, low-global-warming-potential propellants, preservative-free unit-dose systems, pediatric usability, and manufacturing reliability. The strongest near-term opportunity is a reformulated hydrofluoroalkane (HFA) metered-dose inhaler using a lower-GWP propellant, supported by device and product-performance data.

What excipients are used in albuterol sulfate inhalation products?

Albuterol sulfate inhalation products use different excipient systems depending on the delivery platform.

Product platform	Active ingredient	Principal excipients	Commercial function
HFA metered-dose inhaler	Albuterol sulfate equivalent to albuterol	HFA-134a; ethanol in some products	Propulsion, solubilization, valve and actuator performance
Dry-powder inhaler	Albuterol sulfate	Lactose carrier in products such as albuterol sulfate multidose dry-powder inhalers	Powder dispersion, metering, inhalation delivery
Nebulizer solution	Albuterol sulfate	Sodium chloride; water for injection; pH-adjusting agents in some products	Isotonicity, stability, nebulization
Multidose nebulizer solution	Albuterol sulfate	Sodium chloride, preservatives such as benzalkonium chloride in certain products, chelating or pH-adjusting agents depending on product	Microbial control and multidose stability
Unit-dose nebulizer solution	Albuterol sulfate	Sterile aqueous vehicle, commonly isotonic saline	Preservative-free delivery and ease of use

The exact excipient composition is product-specific and must be confirmed against the approved label. FDA labeling identifies HFA-134a as the propellant for Ventolin HFA and identifies ethanol in certain albuterol HFA aerosol products.[1,2]

How do albuterol HFA inhaler excipients affect commercial performance?

HFA metered-dose inhalers are technically sensitive systems. The excipient package affects emitted dose, particle-size distribution, plume geometry, valve performance, actuator deposition, and patient perception.

HFA-134a

HFA-134a is the established propellant for many albuterol sulfate inhalation aerosols. It replaced chlorofluorocarbon propellants under the Montreal Protocol transition and is supported by extensive regulatory and manufacturing experience.

Its commercial advantages include:

• Large supplier base and established pharmaceutical-grade specifications.
• Extensive toxicology and inhalation-use history.
• Compatibility with existing metering valves and canister systems.
• Lower technical and regulatory risk than newer propellants.

Its disadvantages include:

• High global-warming potential relative to emerging alternatives.
• Increasing pressure from environmental policy, procurement standards, and corporate sustainability programs.
• Potential long-term exposure to propellant supply-chain costs and regulatory transition risk.

Ethanol

Ethanol is used in some albuterol HFA products as a cosolvent. It can improve drug solubilization and support solution-based aerosol formulation. Ethanol concentration affects:

• Solubility of albuterol sulfate.
• Evaporation rate after actuation.
• Plume temperature and geometry.
• Droplet size and fine-particle fraction.
• Valve and elastomer compatibility.
• Taste and throat sensation.

A higher ethanol level is not automatically superior. The formulation must balance solubility against spray characteristics, tolerability, extractables, and dose consistency across the canister life.

Oleic acid and suspension systems

Some inhalation aerosol formulations use surfactants such as oleic acid to improve suspension stability and reduce aggregation. A suspension approach can avoid some solubility constraints but introduces other development requirements:

• Particle-size control of micronized albuterol sulfate.
• Suspension homogeneity.
• Shake-dependent dose delivery.
• Sedimentation and creaming behavior.
• Valve retention and actuator deposition.
• Dose uniformity near canister exhaustion.

The formulation route should be selected with the device architecture. A chemically stable formulation can still fail if the valve, actuator, and particle engineering do not maintain consistent emitted dose.

What excipients are used in albuterol dry-powder inhalers?

Dry-powder albuterol products commonly use lactose as a carrier. The active drug is blended with larger lactose particles to improve powder flow, metering, dispersion, and dose reproducibility.

Lactose carrier strategy

Lactose selection affects:

• Carrier particle-size distribution.
• Surface-energy distribution.
• Fine-particle detachment during inhalation.
• Dose uniformity.
• Moisture sensitivity.
• Device resistance and inspiratory-flow requirements.

Lactose-containing products require control of milk-protein contamination. Product labeling for albuterol dry-powder inhalers identifies lactose and warns patients with severe milk-protein allergy.[3]

A lactose-based strategy has a mature supply chain and established regulatory precedent. It is less attractive for patients who require a lactose-free platform or for developers seeking a differentiated formulation. Alternative carrier systems, including mannitol or engineered carrier-free powders, may create differentiation but carry higher development and regulatory risk.

Device dependence

For dry-powder albuterol, the device is part of the commercial product. Key performance variables include:

• Internal resistance.
• Inspiratory-flow threshold.
• Dose-counter reliability.
• Powder retention.
• Humidity protection.
• Patient loading and handling steps.

A lower-resistance device may improve usability for patients with severe airflow limitation, but it can change powder deaggregation and aerodynamic particle-size distribution. Device differentiation therefore requires clinical usability and in vitro performance data, not only a new excipient.

What excipients are used in albuterol nebulizer solutions?

Nebulizer products are generally simpler than inhalation aerosols. A typical unit-dose product contains albuterol sulfate in sterile isotonic aqueous solution, with sodium chloride used to adjust tonicity. The solution may use pH adjustment to maintain chemical stability and comfort during nebulization.

Preservative-free unit-dose opportunity

Preservative-free unit-dose vials are commercially attractive because they avoid patient exposure to benzalkonium chloride and other antimicrobial preservatives used in some multidose products. The main advantages are:

• Lower preservative-related tolerability concerns.
• Simplified pediatric and hospital use.
• Lower risk of dosing contamination after opening.
• Clear differentiation from multidose bottles.

The tradeoff is higher packaging cost, more plastic waste, greater fill-finish complexity, and dependence on reliable sterile unit-dose manufacturing.

Multidose preservative strategy

Multidose solutions may require preservatives to control microbial growth after repeated opening. Benzalkonium chloride has been used in inhalation products, but its concentration must be controlled because repeated exposure can cause bronchoconstrictive or airway-irritating effects in susceptible patients.[4]

Commercially, preservative-free packaging is generally a stronger differentiation path than changing sodium chloride concentration. The excipient system is otherwise close to commodity territory.

What formulation patents protect albuterol sulfate inhalation products?

The core albuterol sulfate active-ingredient patent estate is mature. Commercial protection now depends primarily on product-specific formulation, device, manufacturing, and use claims.

Protection category	Typical claim subject	Commercial relevance
Active ingredient	Albuterol or albuterol sulfate composition	Core protection largely expired
Propellant formulation	HFA composition, cosolvent ratio, suspension or solution system	May protect a specific product architecture
Device	Metering valve, actuator, canister, dose counter, airflow path	Can delay direct device substitution
Dry powder	Carrier morphology, blend, dispersion or inhaler design	May support product differentiation
Nebulizer formulation	Preservative-free composition, concentration, pH, packaging	Usually narrower and product-specific
Manufacturing	Micronization, blending, filling, valve crimping, container preparation	Can create process barriers without fully blocking competitors
Method of use	Pediatric dosing, acute bronchospasm, exercise-induced bronchospasm	Usually limited by prior art and labeling scope

Patent protection must be evaluated against the specific FDA-listed product and current Orange Book entries. A generic albuterol product may be exposed to formulation or device patents even when the active ingredient itself is no longer protected.[5]

When does albuterol sulfate inhalation lose exclusivity?

Albuterol sulfate inhalation products have already lost core small-molecule exclusivity in the United States. Generic entry is established across HFA aerosols, dry-powder products, and nebulizer solutions.

Exclusivity issue	Current commercial position
New chemical entity exclusivity	Expired
Core active-ingredient patent protection	Expired or commercially exhausted
Product-specific formulation patents	May remain for individual products
Device patents	May remain relevant to an inhaler architecture
Pediatric exclusivity	Historical product-specific periods may have applied
Orphan exclusivity	Not generally applicable to standard albuterol rescue indications
Biosimilar exclusivity	Not applicable
Generic substitution	Broadly established, subject to dosage form and device equivalence

The relevant launch risk is therefore not basic albuterol patent expiry. It is whether a competitor can obtain FDA approval for an equivalent product, secure reliable supply, and avoid enforceable patents covering the formulation-device combination.

What is the FDA regulatory status of albuterol sulfate inhalation?

Albuterol sulfate inhalation products are regulated as prescription drug products under several FDA pathways.

HFA metered-dose inhalers

Generic HFA inhalers are generally submitted through abbreviated new drug applications. FDA approval depends on pharmaceutical equivalence, bioequivalence, product-performance testing, device comparability, and manufacturing controls. For orally inhaled products, FDA evaluates parameters such as:

• Single-actuation content.
• Delivered-dose uniformity.
• Aerodynamic particle-size distribution.
• Spray pattern and plume geometry.
• Priming and repriming.
• Number of labeled actuations.
• Container-closure integrity.
• Extractables and leachables.
• Stability under temperature and humidity conditions.

FDA’s product-specific guidance for albuterol sulfate inhalation aerosol identifies the technical expectations for generic development.[6]

Dry-powder inhalers

A generic dry-powder product must demonstrate equivalence in the drug-device combination. The critical issue is not only the chemical composition. The applicant must establish comparable powder performance, device operation, and delivered dose over the labeled life of the inhaler.

Nebulizer solutions

Generic nebulizer solutions are more accessible from a formulation standpoint. The principal requirements involve:

• Same active ingredient and concentration.
• Sterility and microbial controls.
• pH and osmolality.
• Particulate matter.
• Stability.
• Container-closure performance.
• Nebulizer compatibility.
• Preservative content where applicable.

The lower device complexity makes nebulizer solutions attractive for contract manufacturers and regional generic suppliers, although demand is exposed to home-nebulizer utilization and hospital purchasing cycles.

Which companies compete in the albuterol inhalation market?

The U.S. competitive field includes originator, authorized-generic, generic, and device-focused suppliers.

Company or group	Relevant commercial role
GSK	Ventolin HFA originator
Teva	ProAir franchise history, generic albuterol products, dry-powder and aerosol capabilities
Viatris and other generic suppliers	Generic albuterol aerosol and solution supply
Specialty respiratory companies	Device, formulation, and connected-inhaler opportunities
Contract manufacturers	Sterile nebulizer filling, aerosol filling, valve crimping, and packaging

The competitive advantage of an incumbent is often manufacturing scale and distribution rather than patent exclusivity. Albuterol is subject to periodic shortages, especially for sterile inhalation solutions and hospital products. Supplier qualification, dual sourcing, and fill-finish capacity can therefore create more value than a narrow composition patent.

What commercial opportunities exist for albuterol excipients?

Lower-GWP propellant reformulation

The largest strategic opportunity is a transition from HFA-134a to lower-GWP propellants such as HFA-152a or hydrofluoroolefin-based systems. The opportunity is driven by:

• Environmental regulation.
• Health-system procurement requirements.
• Corporate emissions targets.
• Potential future restrictions on high-GWP inhaler propellants.
• Differentiation from established generic products.

The principal barriers are substantial:

• Flammability management for some alternative propellants.
• New canister, valve, elastomer, and actuator compatibility work.
• Dose-delivery comparability.
• Stability and extractables studies.
• Manufacturing-site controls.
• New-device or reformulation regulatory requirements.
• Supply-chain scale for pharmaceutical-grade propellant.

A lower-GWP albuterol inhaler could command commercial value through differentiated branding, institutional contracts, and a longer period of reduced direct substitution if the product uses a proprietary device.

Preservative-free nebulizer products

Preservative-free multidose or unit-dose systems can compete on tolerability, pediatric use, and hospital formulary preference. The best opportunity is in packaging and sterile manufacturing rather than a novel excipient.

Excipient and device co-development

Suppliers can create value by offering integrated platforms combining:

• Pharmaceutical-grade propellant.
• Ethanol or alternative cosolvent systems.
• Low-extractables valve components.
• Compatible elastomers.
• Canister and actuator assemblies.
• Analytical methods for dose and particle-size testing.

An integrated package reduces development risk for smaller generic companies and can support licensing or supply agreements.

Dry-powder carrier innovation

Lactose remains the dominant commercial carrier, but engineered lactose, low-moisture grades, and alternative carriers may support:

• Better dose consistency at low inspiratory flow.
• Reduced humidity sensitivity.
• Improved pediatric delivery.
• Reduced powder retention.
• Device-specific performance advantages.

This opportunity is technically credible but narrower than the low-GWP aerosol opportunity because the product must demonstrate meaningful patient or device benefit.

How strong is the patent estate for albuterol inhalation?

The patent estate is weak for the active ingredient and stronger for selected product architectures.

Estate component	Relative strength	Reason
Albuterol sulfate composition	Low	Mature molecule and extensive prior art
HFA-134a aerosol platform	Low to moderate	Established technology with product-specific variations
Novel low-GWP propellant system	Moderate to strong	Potentially new formulation-device combinations
Dry-powder carrier formulation	Moderate	Narrow claims may protect particle engineering and blend design
Preservative-free nebulizer package	Moderate	Protection may attach to composition, container, or use
Device and valve design	Moderate to strong	Mechanical claims can be difficult to design around
Manufacturing process	Moderate	Useful for trade-secret and process-based advantage

Patent strength depends on claim breadth, prosecution history, written description, enablement, obviousness exposure, and the ability to prove infringement from commercial samples. A patent covering a narrow ethanol concentration or a specific valve component may have limited blocking power against a competitor using a different device architecture.

Are there Paragraph IV challenges for albuterol sulfate inhalation?

Paragraph IV litigation is relevant only where an Orange Book-listed patent remains enforceable against the proposed generic product. For mature albuterol products, the principal generic-entry pathway is established and routine. New Paragraph IV risk may arise when:

• A branded reformulation lists new formulation or device patents.
• A lower-GWP inhaler receives Orange Book-listed patents.
• A dry-powder product has device or carrier claims.
• A generic applicant challenges product-specific patents during ANDA review.

A Paragraph IV strategy for albuterol is more likely to target a reformulated product than the original active ingredient. The commercial value of a challenge depends on the remaining patent term, 180-day exclusivity eligibility, litigation timing, and whether the generic can launch a non-infringing alternative.

What patent litigation and settlement issues affect albuterol products?

Historical albuterol disputes have generally centered on inhaler formulations, device configurations, and generic substitution rather than ownership of the active molecule. For a current product, the relevant questions are:

1. Are patents listed in the FDA Orange Book?
2. Do those patents cover the drug formulation, inhaler device, or method of use?
3. Has an ANDA applicant provided a Paragraph IV certification?
4. Has the sponsor filed an infringement action within the statutory period?
5. Is there a settlement restricting launch timing?
6. Does the settlement permit an authorized generic or license entry?
7. Does the proposed generic use a different device that avoids the patent claims?

Settlement economics are usually driven by the expected value of early entry versus litigation cost. Because albuterol prices are highly competitive, litigation value may be lower than for high-priced specialty medicines. A settlement can still matter if the branded product retains significant hospital, pediatric, or managed-care volume.

What generic launch scenarios exist for albuterol inhalation?

Launch scenario	Likely commercial result
Standard HFA-134a generic aerosol	Rapid price erosion and limited differentiation
Ethanol-adjusted aerosol	Moderate differentiation if performance or tolerability improves
Lower-GWP propellant inhaler	Potential premium or protected branded-generic position
Preservative-free nebulizer solution	Hospital and pediatric differentiation
Alternative dry-powder carrier	Niche opportunity if low-flow performance improves
Integrated inhaler-device platform	Higher development cost but stronger switching barriers
Contract-manufactured sterile solution	Supply-driven opportunity during shortage periods

The most exposed product is a conventional HFA aerosol with no device, packaging, or supply advantage. The most defensible product is a reformulated inhaler with differentiated propellant, proprietary device components, strong manufacturing controls, and an FDA-approved label that supports commercial positioning.

How does albuterol compare with competing rescue inhalers?

Product	Active ingredient	Delivery options	Excipient differentiation	Commercial position
Albuterol sulfate inhalation	Albuterol sulfate	HFA aerosol, DPI, nebulizer solution	Propellant, ethanol, lactose, saline, preservatives	Largest mature generic segment
Levalbuterol inhalation	Levalbuterol	HFA aerosol, nebulizer solution	Similar platform-level options	Potential clinical positioning, higher cost
Ipratropium bromide	Ipratropium	Aerosol, nebulizer	Formulation and combination-device considerations	Different pharmacology and use pattern
Budesonide/formoterol rescue use	Corticosteroid plus long-acting bronchodilator	DPI or aerosol	More complex formulation	Alternative treatment strategy, not direct generic albuterol substitution

Albuterol retains the broadest generic availability and the lowest acquisition cost. Competing products can support premium pricing through clinical positioning, but they do not eliminate the need for low-cost albuterol rescue therapy.

What revenue exposure does albuterol create for manufacturers?

Revenue exposure is high in volume and low in unit margin. Key economic drivers are:

• Generic price erosion.
• Hospital and retail channel mix.
• Sterile fill-finish capacity.
• Propellant and valve costs.
• Device assembly yield.
• Product recalls or supply interruptions.
• Seasonal respiratory demand.
• Contract and government purchasing.

A manufacturer with a single-source sterile solution facility has greater operational exposure than a company with diversified aerosol and nebulizer capacity. A branded lower-GWP inhaler would shift exposure toward device and propellant supply, while a generic nebulizer supplier remains exposed to sterile manufacturing and hospital contracting.

What geographic opportunities exist for albuterol excipient suppliers?

The United States has the most developed generic and Orange Book framework. Europe and other regulated markets create opportunities tied to:

• Propellant-transition requirements.
• National reimbursement and substitution rules.
• Local device registration.
• Pharmaceutical-grade excipient qualification.
• Hospital tender cycles.
• Climate-related procurement standards.

HFA-134a remains widely used globally, but future restrictions may develop unevenly by jurisdiction. Suppliers with validated lower-GWP propellants can benefit from staged market adoption rather than a single global conversion.

Key Takeaways

• Albuterol sulfate inhalation is a mature small-molecule market with expired core exclusivity.
• The main commercial levers are excipient-device integration, low-GWP propellants, preservative-free nebulizer products, and dry-powder performance.
• HFA-134a offers the lowest regulatory and manufacturing risk but carries environmental transition risk.
• Ethanol concentration, suspension stability, valve compatibility, and actuator performance determine HFA product quality.
• Lactose is the established dry-powder carrier, while engineered carriers offer narrower differentiation.
• Preservative-free unit-dose nebulizer solutions are commercially attractive in pediatric and hospital channels.
• Paragraph IV challenges are more relevant to new reformulations and device patents than to the original albuterol molecule.
• The strongest patent opportunity is a lower-GWP propellant-device system supported by formulation, device, and manufacturing claims.
• Manufacturing capacity, sterile fill-finish reliability, and supply continuity can be more valuable than narrow formulation patents.
• Biosimilar competition is not relevant because albuterol sulfate is a chemically synthesized small molecule.

FAQs

Can ethanol be removed from an albuterol HFA inhaler?

Yes, but removal can change drug solubility, plume characteristics, emitted dose, particle-size distribution, and valve performance. A reformulated product requires comparative development and FDA approval.

Is lactose mandatory in an albuterol dry-powder inhaler?

No. Lactose is a common carrier, but alternative carriers or carrier-free engineered powders are possible. They require evidence of dose uniformity, dispersion, stability, and device performance.

Does benzalkonium chloride improve albuterol nebulizer shelf life?

It can support multidose microbial control, but it may create tolerability concerns. Preservative-free unit-dose packaging avoids that tradeoff while increasing packaging and sterile-manufacturing costs.

Can a new albuterol inhaler obtain market exclusivity without a new active ingredient?

Yes. A product may obtain commercial protection through a new device, formulation, propellant system, manufacturing process, or approved combination of these elements. The scope and duration depend on the claims and regulatory pathway.

Is a lower-GWP albuterol propellant commercially viable?

Yes, particularly for branded or differentiated products. Viability depends on pharmaceutical-grade supply, flammability controls where relevant, device compatibility, FDA approval requirements, manufacturing scale, and payer or institutional willingness to recognize the environmental benefit.

References

1. U.S. Food and Drug Administration. (2023). Ventolin HFA (albuterol sulfate) inhalation aerosol prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2023). Albuterol sulfate inhalation aerosol prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2023). ProAir RespiClick (albuterol sulfate) inhalation powder prescribing information. DailyMed.

4. U.S. Food and Drug Administration. (1998). Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products: Chemistry, manufacturing, and controls documentation. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

6. U.S. Food and Drug Administration. (2022). Product-specific guidance for albuterol sulfate inhalation aerosol. FDA.